Physician profile
Dana Dober
NPI 1467645705
$2,220.11
in general payments reported to CMS, 2019-2025
19 companies · $431 in 2025
The $431 reported for 2025 was less than what a typical Foot & Ankle Surgery provider received nationally (typical 2025 total: $424).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $175 · 2020: $173 · 2021: $139 · 2022: $892 · 2023: $101 · 2024: $308 · 2025: $431.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $840.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $840.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Smith+Nephew, INC. | $427.86 | 2022-2024 | Collagenase Santyl |
| Paratek Pharmaceuticals, INC. | $332.25 | 2022-2025 | Nuzyra |
| Convatec INC. | $201.92 | 2023-2025 | |
| Zimmer Biomet Holdings, INC. | $178.35 | 2022 | |
| Organogenesis INC. | $177.19 | 2021-2025 | Affinity |
| Wright Medical Technology, INC. | $173.38 | 2020 | |
| Sandoz INC. | $162.98 | 2019 | |
| Nevro Corp. | $135.21 | 2022 | |
| Boston Scientific Corporation | $96.64 | 2025 | Wavewriter Alpha Prime 16 |
| Abbvie INC. | $88.53 | 2021-2024 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $49.46 | 2022 | |
| Averitas Pharma INC. | $38.24 | 2025 | Qutenza |
| Abbott Laboratories | $32.11 | 2022 | |
| Medtronic, INC. | $28.58 | 2022 | |
| Kerecis Limited | $26.33 | 2025 | Kerecis Surgiclose, Kerecis Graftguide |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vertex Pharmaceuticals Incorporated | $21.93 | 2024 | |
| Solventum Corporation | $19.90 | 2025 | Activ.A.C., Promogran Prisma |
| Synergy Orthopedics, LLC | $17.32 | 2023 | |
| Horizon Therapeutics Plc | $11.93 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dana Dober listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.